Home » Stocks » GLMD

Galmed Pharmaceuticals Ltd. (GLMD)

Stock Price: $2.59 USD -0.06 (-2.26%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $2.70 +0.11 (4.25%) May 7, 7:49 PM
Market Cap 64.97M
Revenue (ttm) n/a
Net Income (ttm) -28.77M
Shares Out 25.08M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $2.59
Previous Close $2.65
Change ($) -0.06
Change (%) -2.26%
Day's Open 2.54
Day's Range 2.51 - 2.70
Day's Volume 360,907
52-Week Range 2.25 - 6.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TEL AVIV, Israel, May 3, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory dis...

4 days ago - PRNewsWire

TEL AVIV, Israel, March 18, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the live...

1 month ago - PRNewsWire

TEL AVIV, Israel, March 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company today announced the treatment of the f...

1 month ago - PRNewsWire

TEL AVIV, Israel, March 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol...

1 month ago - PRNewsWire

TEL AVIV, Israel, Feb. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...

2 months ago - PRNewsWire

TEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...

3 months ago - PRNewsWire

TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...

4 months ago - PRNewsWire

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

TEL-AVIV, Israel and SHANGHAI, Sept. 10, 2020 /PRNewswire/ -- Gannex Pharma Co.

7 months ago - PRNewsWire

SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- Gannex Pharma Co.

7 months ago - PRNewsWire

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

9 months ago - PRNewsWire

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

9 months ago - PRNewsWire

Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

TEL AVIV, Israel, May 14, 2020 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver t...

11 months ago - PRNewsWire

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Top Ranked Momentum Stocks to Buy for December 4th

Other stocks mentioned: CAAS, GSAT, SAVA
1 year ago - Zacks Investment Research

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Other stocks mentioned: AGN, CBAY, CNAT, ICPT, MDGL
1 year ago - Zacks Investment Research

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CPE, SIEN, TELL, VKTX
1 year ago - 24/7 Wall Street

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.

Other stocks mentioned: INO, LJPC, MNKD, VKTX
2 years ago - 24/7 Wall Street

Galmed Pharmaceuticals delivered earnings and revenue surprises of -58.33% and -100.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

About GLMD

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it eng... [Read more...]

Industry
Biotechnology
IPO Date
Mar 13, 2014
CEO
Allen Baharaff
Employees
18
Stock Exchange
NASDAQ
Ticker Symbol
GLMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GLMD stock is "Buy." The 12-month stock price forecast is 16.40, which is an increase of 533.20% from the latest price.

Price Target
$16.40
(533.20% upside)
Analyst Consensus: Buy